Clinical trials
Phase 1 Respiratory Distress Syndrome trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
52 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 10 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Unknown status | 11 |
| Withdrawn | 10 |
| Terminated | 5 |
| Not yet recruiting | 3 |
| Recruiting | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Brigham and Women's Hospital | 2 |
| ASST Fatebenefratelli Sacco | 1 |
| Altor BioScience | 1 |
| Aqualung Therapeutics Corp. | 1 |
| Asia Cell Therapeutics (Shanghai) Co., Ltd. | 1 |
| Bayer | 1 |
| Beijing Chao Yang Hospital | 1 |
| BioCardia, Inc. | 1 |
| BioSpring Medical Co., Ltd | 1 |
| Biotech Pharmaceutical Co., Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Respiratory Distress Syndrome | 52 |
| COVID-19 | 9 |
| Acute Lung Injury | 8 |
| Hypoxia | 3 |
| Lung Diseases | 3 |
| Sepsis | 3 |
| Coronavirus Infections | 2 |
| Hypertension, Pulmonary | 2 |
| Lung Injury | 2 |
| Pneumonia | 2 |
Trials
Showing 1 to 25 of 52. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.